Cargando…
Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies
BACKGROUND: Alpha-particle-emitting radiotherapies are of great interest for the treatment of disseminated cancer. Actinium-225 ((225)Ac) produces four α-particles through its decay and is among the most attractive radionuclides for use in targeted radiotherapy applications. However, supply issues f...
Autores principales: | Abou, Diane S., Zerkel, Patrick, Robben, James, McLaughlin, Mark, Hazlehurst, Tim, Morse, David, Wadas, Thaddeus J., Pandya, Darpan N., Oyama, Reiko, Gaehle, Gregory, Nickels, Michael L., Thorek, Daniel L.J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc., publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242709/ https://www.ncbi.nlm.nih.gov/pubmed/35695807 http://dx.doi.org/10.1089/cbr.2022.0010 |
Ejemplares similares
-
The determination of the radiochemical purity of Actinium-225 radiopharmaceuticals: a conundrum
por: Kleynhans, Janke, et al.
Publicado: (2022) -
Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development
por: Pandya, Darpan N., et al.
Publicado: (2017) -
Recent Advances in Zirconium-89 Chelator Development
por: Bhatt, Nikunj B., et al.
Publicado: (2018) -
Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases
por: Patel, Chirayu M., et al.
Publicado: (2021) -
Development of Targeted Alpha Particle Therapy for Solid Tumors
por: Tafreshi, Narges K., et al.
Publicado: (2019)